<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496324</url>
  </required_header>
  <id_info>
    <org_study_id>RB7-UK-1509</org_study_id>
    <secondary_id>2015-003894-13</secondary_id>
    <nct_id>NCT03496324</nct_id>
  </id_info>
  <brief_title>Ibuprofen 4% (w/v) Pivotal Bioequivalence Study</brief_title>
  <official_title>A Randomised, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic Study Comparing a 4% (w/v) Suspension of Ibuprofen With a Reference 2% (w/v) Suspension of Ibuprofen in the Fed and Fasted States.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence evaluation of Nurofen for Children® with reference formulation of Algifor®
      Junior by determining and comparing the rate and extent of absorption in both fed and fasted
      states
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Actual">May 6, 2016</completion_date>
  <primary_completion_date type="Actual">May 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
    <description>One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Kel) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
    <description>Kel was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximized the adjusted R2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
    <description>AUC0-inf was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of AUC0-t/AUC0-inf (AUCR)</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Half-life (T1/2) of Ibuprofen</measure>
    <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 7 (follow-up)</time_frame>
    <description>Mild = Adverse event (AE) did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the investigational medicinal product (IMP).
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioequivalence of the Test Formulation</condition>
  <arm_group>
    <arm_group_label>Test (fed): Nurofen for Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test (fasted): Nurofen for Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference (fed): Algifor Junior</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference (fasted): Algifor Junior</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nurofen for Children®</intervention_name>
    <description>Nurofen for Children® 400 mg/10 ml</description>
    <arm_group_label>Test (fasted): Nurofen for Children</arm_group_label>
    <arm_group_label>Test (fed): Nurofen for Children</arm_group_label>
    <other_name>NfC®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Algifor® Junior</intervention_name>
    <description>Algifor® Junior 400 mg/20 ml</description>
    <arm_group_label>Reference (fasted): Algifor Junior</arm_group_label>
    <arm_group_label>Reference (fed): Algifor Junior</arm_group_label>
    <other_name>Ibuprofen oral suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who had given written informed consent.

          2. Age: ≥18 years ≤50 years.

          3. Sex: Male or female subjects who were eligible for entry.

          4. Female subject of childbearing potential with a negative pregnancy test at the
             screening visit and who were willing to use an effective method of contraception, if
             applicable (unless of non-childbearing potential or where abstaining from sexual
             intercourse was in line with the preferred and usual lifestyle of the subject) from
             first dose until 3 months after the final dose of Investigational Medicinal Product
             (IMP). Effective forms of contraception included: established use of oral, injected or
             implanted hormonal methods of contraception, placement of an intrauterine device (IUD)
             or intrauterine system (IUS), barrier methods of contraception: condom or occlusive
             cap (diaphragm or cervical/vault caps) with spermicidal
             foam/gel/film/cream/suppository, male sterilisation (with the appropriate
             post-vasectomy documentation of the absence of sperm in the ejaculate).

          5. Female subject of non-child bearing potential with negative pregnancy test at the
             screening visit. For the purposes of this study, this was defined as the subject being
             amenorrheic for at least 12 consecutive months or at least 4 months post-surgical
             sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy
             with or without hysterectomy). Menopausal status was confirmed by demonstrating at
             screening that levels of follicle stimulating hormone (FSH) fell within the respective
             pathology reference range. In the event a subject's menopause status had been clearly
             established (for example, the subject indicated she had been amenorrheic for 10
             years), but FSH levels were not consistent with a post-menopausal condition,
             determination of subject eligibility was at the discretion of the Principal
             Investigator following consultation with the Sponsor's Responsible Physician.

          6. Male subject willing to use an effective method of contraception, if applicable
             (unless anatomically sterile or where abstaining from sexual intercourse in line with
             the preferred and usual lifestyle of the subject) from first dose until 3 months after
             the final dose of IMP.

          7. Healthy subjects as determined by past medical history, physical examination, vital
             signs, electrocardiogram (ECG), and laboratory tests at screening.

          8. Healthy subjects with a body mass index (BMI) of ≥20 and ≤27 kg/m2.

        Exclusion Criteria:

          1. Pregnant or lactating females.

          2. A history and/or presence of significant disease of any body system, including
             psychiatric disorders as specified in Chapter 5 of the International Classification of
             Diseases (ICD) 10.

          3. Any condition that may have interfered with the absorption, distribution, metabolism
             or excretion of drugs.

          4. A history of allergy or intolerance (including angioedema, urticaria, bronchospasm and
             rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal
             anti-inflammatory drugs (NSAIDs), or the excipients of the formulations.

          5. A history of or active peptic or duodenal ulcers or gastrointestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          6. A history of frequent dyspepsia, e.g. heartburn or indigestion.

          7. A history of migraine.

          8. Users of nicotine products i.e. current smokers and ex-smokers who had smoked within
             the 6 months prior to dosing with the study medication or users of cigarette
             replacements (e.g. e-cigarettes, nicotine patches or gums).

          9. A history of substance abuse (including alcohol).

         10. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc. total
             caffeine intake per day above 300 mg (1 cup of coffee equated to 50 mg)).

         11. Those with positive screen/test for drugs of abuse including alcohol on any occasion
             throughout the study.

         12. Ingestion of a prescribed drug at any time in the 14 days before dosing with study
             medication (excluding hormonal contraceptives and hormone replacement therapy), or
             consumption of enzyme inhibitors or inducers during the previous month (such as
             barbiturates, carbamazepine, erythromycin, phenytoin, etc.).

         13. Ingestion of an over-the-counter preparation within 7 days before dosing with study
             medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and
             other NSAID.

         14. Donation of blood in quantity &gt;400 mL, e.g., to the blood transfusion service in the
             previous 12 weeks before enrolment into the study.

         15. Known human immune deficiency virus (HIV) positive status, or a positive viral
             serology screen.

         16. Topical use of ibuprofen within 7 days before dosing with IMP.

         17. Those previously randomized into this study.

         18. Employee at study site.

         19. Partner or first degree relative of the Investigator.

         20. Those who have participated in a clinical trial in the previous 12 weeks.

         21. Those unable, in the opinion of the Investigator, to comply fully with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <results_first_submitted>May 11, 2018</results_first_submitted>
  <results_first_submitted_qc>February 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted in single-site in the United Kingdom.</recruitment_details>
      <pre_assignment_details>Total 71 subjects were screened. Of these, 38 subjects were screen failures, 2 were withdrew consent, 7 were reserve subjects. Subjects randomized were 24.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1—BACD: Test (Fed) - Nurofen for Children</title>
          <description>B = Nurofen for Children® 400 mg/10 ml (Test fasted)
A = Nurofen for Children® 400 mg/10 ml (Test fed)
C = Algifor® Junior 400 mg/20 ml (Reference fed)
D = Algifor® Junior 400 mg/20 ml (Reference fasted)</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2—DCAB: Test (Fasted) - Nurofen for Children</title>
          <description>D = Algifor® Junior 400 mg/20 ml (Reference fasted)
C = Algifor® Junior 400 mg/20 ml (Reference fed)
A = Nurofen for Children® 400 mg/10 ml (Test fed)
B = Nurofen for Children® 400 mg/10 ml (Test fasted)</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3—ADBC: Reference (Fed) - Algifor Junior</title>
          <description>A = Nurofen for Children® 400 mg/10 ml (Test fed)
D = Algifor® Junior 400 mg/20 ml (Reference fasted)
B = Nurofen for Children® 400 mg/10 ml (Test fasted)
C = Algifor® Junior 400 mg/20 ml (Reference fed)</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4—CBDA: Reference (Fasted) - Algifor Junior</title>
          <description>C = Algifor® Junior 400 mg/20 ml (Reference fed)
B = Nurofen for Children® 400 mg/10 ml (Test fasted)
D = Algifor® Junior 400 mg/20 ml (Reference fasted)
A = Nurofen for Children® 400 mg/10 ml (Test fed)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 7: Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Nurofen for Children® 400 mg/10 mL single-oral dose under fasted and fed conditions.
Algifor® Junior 400 mg/20 mL single-oral dose under fasted and fed conditions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.68" spread="11.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.692" spread="0.0935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.82" spread="2.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Ibuprofen</title>
        <description>One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</description>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>Pharmacokinetics (PK) Parameter Summary Set population: All subjects from the PK dataset with evaluable PK parameters for each treatment period. (PK Dataset: All subjects from the safety population with evaluable plasma concentrations).</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Ibuprofen</title>
          <description>One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</description>
          <population>Pharmacokinetics (PK) Parameter Summary Set population: All subjects from the PK dataset with evaluable PK parameters for each treatment period. (PK Dataset: All subjects from the safety population with evaluable plasma concentrations).</population>
          <units>μg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.503" spread="7.5696"/>
                    <measurement group_id="O2" value="25.162" spread="6.9668"/>
                    <measurement group_id="O3" value="33.843" spread="3.7858"/>
                    <measurement group_id="O4" value="26.432" spread="6.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was demonstrated between NfC® and Algifor® Junior if each 90% confidence interval (CI) (rounded to 2 decimal places) for the ratio between least square geometric means (test / reference) lay within 80% and 125% for Cmax.</non_inferiority_desc>
            <param_type>Geometric Least Square Mean</param_type>
            <param_value>94.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.81</ci_lower_limit>
            <ci_upper_limit>103.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was demonstrated between NfC® and Algifor® Junior if each 90% CI (rounded to 2 decimal places) for the ratio between least square geometric means (test / reference) lay within 80% and 125% for Cmax.</non_inferiority_desc>
            <param_type>Geometric Least Square Mean</param_type>
            <param_value>111.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.84</ci_lower_limit>
            <ci_upper_limit>120.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen</title>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen</title>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>min*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6169.662" spread="1199.1785"/>
                    <measurement group_id="O2" value="5754.831" spread="1056.5014"/>
                    <measurement group_id="O3" value="5960.054" spread="832.1342"/>
                    <measurement group_id="O4" value="5482.340" spread="827.2913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was demonstrated between NfC® and Algifor® Junior if each 90% CI (rounded to 2 decimal places) for the ratio between least square geometric means (test / reference) lay within 80% and 125% for AUC0-t.</non_inferiority_desc>
            <param_type>Geometric Least Square Mean</param_type>
            <param_value>101.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.28</ci_lower_limit>
            <ci_upper_limit>107.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was demonstrated between NfC® and Algifor® Junior if each 90% CI (rounded to 2 decimal places) for the ratio between least square geometric means (test / reference) lay within 80% and 125% for AUC0-t.</non_inferiority_desc>
            <param_type>Geometric Least Square Mean</param_type>
            <param_value>104.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.4</ci_lower_limit>
            <ci_upper_limit>107.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Kel) of Ibuprofen</title>
        <description>Kel was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximized the adjusted R2.</description>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel) of Ibuprofen</title>
          <description>Kel was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximized the adjusted R2.</description>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>1/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00646" spread="0.000763"/>
                    <measurement group_id="O2" value="0.00532" spread="0.00119"/>
                    <measurement group_id="O3" value="0.00668" spread="0.000763"/>
                    <measurement group_id="O4" value="0.00577" spread="0.000865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen</title>
        <description>AUC0-inf was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t.</description>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen</title>
          <description>AUC0-inf was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t.</description>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>min*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6255.821" spread="1229.6414"/>
                    <measurement group_id="O2" value="5982.084" spread="1118.9361"/>
                    <measurement group_id="O3" value="6032.841" spread="843.8379"/>
                    <measurement group_id="O4" value="5609.733" spread="862.2304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of AUC0-t/AUC0-inf (AUCR)</title>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of AUC0-t/AUC0-inf (AUCR)</title>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.987" spread="0.0066"/>
                    <measurement group_id="O2" value="0.963" spread="0.0384"/>
                    <measurement group_id="O3" value="0.988" spread="0.0052"/>
                    <measurement group_id="O4" value="0.978" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Ibuprofen</title>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Ibuprofen</title>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="43.59"/>
                    <measurement group_id="O2" value="65.8" spread="24.79"/>
                    <measurement group_id="O3" value="65" spread="33.81"/>
                    <measurement group_id="O4" value="74.9" spread="42.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration Half-life (T1/2) of Ibuprofen</title>
        <time_frame>Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose</time_frame>
        <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Half-life (T1/2) of Ibuprofen</title>
          <population>PK Parameter Summary set population. One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.854" spread="13.1303"/>
                    <measurement group_id="O2" value="138.894" spread="41.0392"/>
                    <measurement group_id="O3" value="104.975" spread="11.6362"/>
                    <measurement group_id="O4" value="122.752" spread="19.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>Mild = Adverse event (AE) did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the investigational medicinal product (IMP).
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
        <time_frame>Up to Day 7 (follow-up)</time_frame>
        <population>Safety population: All subjects who received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Fasted): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O2">
            <title>Test (Fed): Nurofen for Children</title>
            <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
          </group>
          <group group_id="O3">
            <title>Reference (Fasted): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
          <group group_id="O4">
            <title>Reference (Fed): Algifor Junior</title>
            <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>Mild = Adverse event (AE) did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the investigational medicinal product (IMP).
Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP</description>
          <population>Safety population: All subjects who received at least 1 dose of IMP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Conditional/Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Unassessable/Unclassifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 7 (Follow-up)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test (Fasted): Nurofen for Children</title>
          <description>Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
        </group>
        <group group_id="E2">
          <title>Test (Fed): Nurofen for Children</title>
          <description>Nurofen for Children® 400 mg/10 ml by mouth under fed condition
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Nurofen for Children®: Nurofen for Children® 400 mg/10 ml</description>
        </group>
        <group group_id="E3">
          <title>Reference (Fasted): Algifor Junior</title>
          <description>Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
        </group>
        <group group_id="E4">
          <title>Reference (Fed): Algifor Junior</title>
          <description>Algifor® Junior 400 mg/20 ml by mouth under fed condition.
Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.
Algifor® Junior: Algifor® Junior 400 mg/20 ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser Healthcare (UK) Ltd</organization>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

